Live from the NIH registry
Studies recruiting near Waterbury right now
Top 25 of 1,147 recruiting studies, sorted by proximity — each links to its official registry page
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
Phase 3
Interventional 115 participants sought
Yale University (Adults and Pediatrics) — New Haven, Connecticut (18.2 mi)
· Sponsor: Pierre Fabre Medicament
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Generalized Myasthenia Gravis
N/A
Observational 500 participants sought
Clinical Trial Site — New Haven, Connecticut (18.2 mi)
· Sponsor: Alexion Pharmaceuticals, Inc.
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Phase 1
Interventional 604 participants sought
Smilow Cancer Hospital (Yale University) — New Haven, Connecticut (18.2 mi)
· Sponsor: Revolution Medicines, Inc.
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Yale University — New Haven, Connecticut (18.2 mi)
· Sponsor: National Cancer Institute (NCI)
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
Alcohol Use Disorder, Cannabis Use Disorder
N/A
Interventional 294 participants sought
UConn Health — Farmington, Connecticut (15.4 mi)
· Sponsor: Massachusetts General Hospital
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis
Phase 2
Interventional 168 participants sought
DaVita Clinical Research — Middlebury, Connecticut (5.2 mi)
· Sponsor: R1 Therapeutics
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
HNSCC, ESCC
Phase 1
Interventional 150 participants sought
Normunity Investigational Site — New Haven, Connecticut (18.2 mi)
· Sponsor: Normunity AccelCo, Inc.
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
N/A
Interventional 400 participants sought
Yale University School of Medicine — New Haven, Connecticut (18.2 mi)
· Sponsor: Medtronic MiniMed, Inc.
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
Acute Leukemia, Newly Diagnosed
N/A
Observational 1,365 participants sought
Hartford Healthcare Cancer Institute @ Hartford Hospital — Hartford, Connecticut (23.0 mi)
· Sponsor: Memorial Sloan Kettering Cancer Center
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
Smilow Cancer Hospital-Waterbury Care Center — Waterbury, Connecticut (0.8 mi)
· Sponsor: SWOG Cancer Research Network
CLOZAPINE Response in Biotype-1
Schizophrenia, Schizoaffective Disorder
Phase 4
Interventional 524 participants sought
Hartford Healthcare — Hartford, Connecticut (23.0 mi)
· Sponsor: University of Texas Southwestern Medical Center
OssiMend BA in Posterolateral Instrumented Lumbar Fusion
Spinal Disease, Degenerative Disc Disease
N/A
Observational 120 participants sought
Hartford Hospital — Hartford, Connecticut (23.0 mi)
· Sponsor: Collagen Matrix
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Advanced Prostate Cancer, Metastatic Prostate Cancer
Phase 1
Interventional 210 participants sought
Yale Cancer Center — New Haven, Connecticut (18.2 mi)
· Sponsor: Genentech, Inc.
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
N/A
Observational 30 participants sought
Yale School Of Medicine — New Haven, Connecticut (18.2 mi)
· Sponsor: Takeda
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
Focal Onset Seizures
Phase 2
Interventional 216 participants sought
Yale University — New Haven, Connecticut (18.2 mi)
· Sponsor: Supernus Pharmaceuticals, Inc.
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation, HER2- Negative Breast Cancer
Phase 3
Interventional 540 participants sought
Yale-New Haven Hospital-Yale Cancer Center — New Haven, Connecticut (18.2 mi)
· Sponsor: Relay Therapeutics, Inc.
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Colitis, Ulcerative
Phase 3
Interventional 882 participants sought
Connecticut Children's Medical Center — Hartford, Connecticut (23.0 mi)
· Sponsor: Janssen Research & Development, LLC
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Phase 3
Interventional 450 participants sought
Yale-New Haven Hospital — New Haven, Connecticut (18.2 mi)
· Sponsor: Eli Lilly and Company
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Advanced Solid Tumor
Phase 1
Interventional 105 participants sought
Yale Cancer Center — New Haven, Connecticut (18.2 mi)
· Sponsor: BeOne Medicines
ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection
Clostridium Difficile Infection Recurrence
Phase 2
Interventional 20 participants sought
Gastroenterolgy Center of Conneticut — Hamden, Connecticut (13.3 mi)
· Sponsor: Acurx Pharmaceuticals Inc.
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Ulcerative Colitis, Ulcerative Colitis Chronic
Phase 3
Interventional 150 participants sought
Connecticut Children's Medical Center — Hartford, Connecticut (23.0 mi)
· Sponsor: Eli Lilly and Company
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Non-small Cell Lung Cancer, Histiocytic Neoplasm
Phase 1, Phase 2
Interventional 554 participants sought
Yale University School of Medicine - Yale Cancer Center — New Haven, Connecticut (18.2 mi)
· Sponsor: Institut de Recherches Internationales Servier
Longitudinal Neural Fingerprinting of Opioid-use Trajectories
Opioid Use Disorder
N/A
Interventional 10 participants sought
MRRC at The Anlyan Center — New Haven, Connecticut (18.2 mi)
· Sponsor: Yale University
Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)
Pediatric Cancer
N/A
Observational 35 participants sought
Connecticut Children's Medical Center — Hartford, Connecticut (23.0 mi)
· Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Neuroblastoma
Phase 2
Interventional 98 participants sought
Connecticut Children's Hospital — Hartford, Connecticut (23.0 mi)
· Sponsor: Giselle Sholler